Skip to search formSkip to main contentSkip to account menu

ASP2215

Known as: ASP-2215 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Aniline CompoundsGilteritinibPyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Acute myeloid leukemia (AML) is a heterogeneous disease with cure rates of only 30-40% in patients <60 years old. Cytogenetic and… 
2016
2016
Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia
Background FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia (AML… 
2014
2014
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML).
7071 Background: Patients with AML harboring internal tandem duplication (ITD) of FLT3 have a poor prognosis following the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)